Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Core Viewpoint - Pasithea Therapeutics, a clinical-stage biotechnology company, has announced a public offering of shares and warrants to raise approximately $5.0 million for various corporate purposes, including ongoing research and clinical trials [1][4]. Group 1: Offering Details - The company is offering 3,571,428 shares of common stock at a price of$1.40 per share, along with Series C and Series D warrants [1][2]. - The Series C warrants will have an exercise price of $1.40 and will expire five years after issuance, while the Series D warrants will also have an exercise price of$1.40 but will expire 18 months after issuance [2]. - The closing of the offering is expected to occur on or about May 7, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including ongoing research, pre-clinical studies, clinical trials, and the development of new technologies [4]. - The company may also invest in or acquire synergistic companies and engage in licensing activities related to its current and future product candidates [4]. Group 3: Company Overview - Pasithea Therapeutics focuses on the discovery and development of innovative treatments for central nervous system disorders, RASopathies, and MAPK pathway-driven tumors [7].